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SUMMARY - Parkinson's disease is one of the most common neurodegenerative diseases cau-
sed by degeneration of dopaminergic neurons in substantia nigra . The neuropathologic hallmark of
Parkinson's disease is the presence of Lewy bodies composed mostly of alpha-synuc1ein and ubiqu-
itin. It is believed that the occurrence of Parkinson's disease is due to a combination of genetic and
environmental factors, but the exact mechanism of Parkinson's disease development is not fully
elucidated. The most characteristic motor symptoms for Parkinson's disease include bradykinesia,
rigidity, resting tremor and postural instability, while many patients also have non-motor signs and
symptoms. The key therapeutic agent in the treatment of Parkinson's disease is L-dopa, and the
others are dopaminergic agents, monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyl-
transferase (COMT) inhibitors, amantadine and anticholinergic agents.
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Introduction
Parkinson's disease (PD) is named after James Par-
kinson, an English physician who described it in his
work entitled An assay on the shaking palsy from 1817.
The disease is a progressive neurodegenerative disorder
caused by the loss of dopaminergic nigrostriatal neu-
rons. The most prominent clinical features include rest-
ing tremor, rigidity, bradykinesia and postural instabili-
ty. Idiopathic PD is primarily caused by degeneration of
dopaminergic nigrostriatal neurons. First clinical symp -
toms ofPD occur after at least 60%-80% ofnigrostriatal
dopaminergic neurons have lost their function'.
Pathophysiology
The major neuropathologic finding in PD is the
loss of pigmented dopaminergic neurons in the pars
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compacta of substantia nigra and the presence of
Lewy bodies. Lewy bodies are concentric, eosino-
philic, cytoplasmic inclusions with peripheral halos
and dense cores composed mainly of alpha-synuclein.
Lewy bodies stain for alpha-synuclein and also for
ubiquitin. The presence of Lewy bodies within pig-
mented neurons of the substantia nigra is character-
istic of idiopathic PD. Lewy bodies are also found in
other parts of the brain such as locus ceruleus, nucleus
basalis, intermediolateral column of the spinal cord,
cortex, and other areas. Braak et ai. demonstrated the
Lewy body pathology in PD to begin in the olfactory
bulb and lower brainstem (Braak stage 1), ascend-
ing to upper brainstem (Braak stage 2), midbrain and
nigrostriatal dopaminergic neurons (Braak stage 3),
archicortex (Braak stage 4), and primary and associa-
tive parts of the cortex (Braak stages 5 and 6)2 Early
stages (1-2) are associated with symptoms such as loss
of the sense of smell and rapid eye movement (REM)
sleep behavior disorder (RBD)3. Braak stage 3 corre-
lates with development of motor symptoms when pa-
tients may exhibit bradykinesia, rigidity and tremor.
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In Braak stages 4, 5 and 6, patients may exhibit cogni-
tive dysfunction and dementia.
This sequence of Lewy body pathology favors ol-
factory testing as a possible screening method for pre-
clinical PD. Impaired olfactory function was found in
40 of 49 (82%) PD patients. The sensitivity of olfac-
tory dysfunction for PD was 0.82, specificity 0.82 and
predictive value 0.774
Epidemiology
PD is one of the most common neurologic disor-
ders, affecting approximately 1% of individuals older
than 60. The incidence has been estimated to 4.5-
21 cases per 100,000 population per year. Estimates
of PD prevalence range from 18 to 328 per 100,000
population, with most studies yielding a prevalence
of approximately 120 per 100,000. The incidence and
prevalence of PD increase with age. PD is about 1.5
times more common in men than in women. The av-
erage age at onset is 60 years, while the onset in per-
sons younger than 40 is uncommon'.
Etiology
Idiopathic PD is believed to be due to a combina-
tion of genetic and environmental factors. Environ-
mental risk factors associated with the development of
PD include use of pesticides, living in a rural setting,
consumption of well water, exposure to herbicides,
and proximity to industrial plants or quarries, while
cigarette smoking and caffeine consumption have
some protective role6,7.
Several individuals have been identified that de-
veloped parkinsonism after self-injection of l-mcthyl-
4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)8
The oxidation hypothesis suggests that dopamine
oxidative metabolism produces free radicals that could
playa role in the development or progression of PD.
The oxidative metabolism of dopamine leads to the
formation of hydrogen peroxide. Hydrogen peroxide
normally is cleared rapidly by glutathione. If hydro-
gen peroxide is not cleared adequately, it may lead
to the formation of highly reactive hydroxyl radicals
that can react with cell membrane lipids to cause lipid
peroxidation and cell damage. In PD, the levels of re-
duced glutathione are decreased, suggesting the loss
of protection against formation of free radicals. Iron
is increased in the substantia nigra and may serve as
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a source of donor electrons, thereby promoting the
formation of free radicals. Increased iron accumula-
tion in substantia nigra could be the cause of hyper-
echogenicity seen in most PD patients on transcranial
sonography", Thus, PD is associated with an increased
dopamine turnover, decreased protective mechanisms
(glutathione), increased iron (a pro-oxidation mol-
ecule), and evidence of increased lipid peroxidation.
Mutations in the alpha-synuclein gene can cause
PD. It is now clear that these mutations are an ex-
ceedingly rare cause of PD. Alpha-synuclein is a ma-
jor component of Lewy bodies in all PD cases. Lewy
bodies contain alpha-synuclein, and most also contain
ubiquitin, which conjugates with proteins targeted for
proteolysis. Abnormal aggregation of alpha-synuclein
into filamentous structures may precede ubiquitiza-
tion. One hypothesis states that the mutation alters
the configuration of alpha-synuclein from alpha he-
lix to beta-structure that could aggregate into sheets.
Therefore, PD may be associated with abnormal fold-
ing of alpha-synuclein, leading to excessive aggrega-
tion causing neuronal death. Also, PD could be caused
by abnormalities of the proteosome system responsible
for clearing abnormal proteins.
Clinical Features
PD may have a long premotor stage. Features that
commonly precede the onset of motor signs include
decreased sense of smell and REM behavior disorder
(RBD). RBD is a sleep disorder in which there is the
loss of normal atony during REM sleep and it is com-
mon throughout the course of PD.
The onset of motor signs in PD is typically asym-
metric. About 20% of patients first experience clumsi-
ness in one hand. Over time, patients notice tremor and
symptoms related to progressive bradykinesia, rigidity,
and postural instability. Resting tremor usually begins
in one upper extremity and initially may be intermittent.
The amplitude increases with stress and resolves during
sleep. Over time, axial posture becomes progressively
flexed and strides become shorter. Decreased swallow-
ing may lead to excess saliva in the mouth and drooling.
Symptoms of autonomic dysfunction are common and
include constipation, sweating abnormalities, sexual
dysfunction, and seborrheic dermatitis".
Dementia generally occurs late in PD and affects
15%-30% of patients. Cognitive dysfunction within a
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year of onset of motor features suggests the diagnosis
of Lewy body disease.
Diagnosis
PD is diagnosed by clinical criteria; there is no de-
finitive test for the diagnosis. Historically, pathologic
confirmation of the hallmark ofLewy body on autop-
sy has been considered the criterion standard for the
diagnosis". Diagnostic criteria have been developed
by the UK Parkinson's Disease Society Brain Bank"
and National Institute of Neurological Disorders and
Stroke (NINDS)13 Differentiating PD from other
forms of parkinsonism can be challenging early in the
course of the disease, when signs and symptoms over-
lap with other syndromes.
Therapy
Pharmacological treatment ofPD includes L-dopa
usually combined with 3.4-dihydroxyphenylalanine
(DOPA) decarboxylase inhibitors (such as carbi-
dopa and benserazide that reduce decarboxylation of
levodopa before it reaches the brain), selective mono-
amine oxidase-B (MAO-B) inhibitors (selegiline and
rasagiline), catechol-O-methyltransferase (COMT)
inhibitors (entacapone and tolcapone), dopamine re-
ceptor agonists (pramipexole and ropirinile), amanta-
dine and anticholinergics. Patients with PD respond
to these agents with improvement in disease signs and
symptoms.
Levodopa, a dopamine precursor, is considered to
be the most effective antiparkinsonian agent. In ran-
domized trials comparing levodopa and a dopamine
agonist, activities of daily living and motor features
of PD improved with levodopa by about 40% to 50%
(as compared with approximately 30% with dopamine
agonists).
Dopamine agonists are slightly less effective than
levodopa, they are alternative first-line agents for PD,
especially in younger patients. In general, anticholin-
ergic agents are not used for PD because of associated
adverse effects. However, they are sometimes added if
tremor is particularly bothersome and unresponsive to
other drugs, although evidence is lacking to support
particular efficacy of these agents in treating tremor.
MAO-B inhibitors and amantadine have fewer ad-
verse effects and require little titration to reach thera-
peutic dosesv".
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Saietak
PARKINSONOVA BOLEST
R. Bene, S. AntiC, M. Budifii, M. Lisak, Z. Trkanjec, V Demarin i S. Podobnik-Sarkanji
Parkinson's disease
Parkinsonova bolest [e jedna od najcescrh neurodegenerativnih bolesti koju uzrokuje degeneracija dopammergrcnrh
neurona u supstanciji nigri. Xeuropatclosko obiljezje Parkinsonove bolesti je nalaz Lewyjevih tjelesaca koja su najvecrm
dijelom gradena od alfa sinukleina i ubikvitina. Pojavu Parkinsonove bolesti uzrokuje medudjelovanje genetskih cimbeni-
ka i cimbenika iz okohsa, ali tocan mehanizam nastanka bolesti nije u potpunosti poznat. Najznacajmji motorni simptomi
bolesti su bradikinezija, rigiditet, tremor u mirovanju i posturalna nestabilnost. Najznacajniji lijek u lijecenju Parkinsonove
bolesti je L-dopa, a primjenjuju se i dopammergicni agonisti, inhibitori monoaminooksidaze B (MAO-B), inhibitori ka-
tehol-O-metil transferaze (COMT), amantadin i anukolmergicni lijekovi.
Kljucne rijeci: Parkinsonova bolest - etiologija; Parkinsonova bolest - diJagnostika; Parkinsonova bolest - terapiJa
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